Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata.

Objective: To assess the effect of ultra low-dose mifepristone on uterine size, pain, bleeding and quality of life among women with symptomatic leiomyomata.

Study Design: Open-label cohort study of 2.5mg mifepristone orally among adult women with at least moderately severe symptoms related to leiomyomata and total uterine volume of greater than 160 cm(3), or at least one myoma of greater than 2.